<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="43%"></col>
<col width="57%"></col>
<thead>
<tr>
<th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Interacting Drug</content>
</th>
<th align="center" stylecode="Rrule Botrule Toprule " valign="top">
<content stylecode="bold">Interaction</content>
</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Drugs known to prolong QT interval (e.g., Class IA and Class III antiarrhythmic agents).</paragraph>
</td>
<td stylecode="Rrule Toprule Botrule " valign="top">
<paragraph>Quinine sulfate capsules, USP prolongs QT interval, ECG abnormalities including QT prolongation and Torsades de Pointes. Avoid concomitant use (
             
     
        <linkhtml href="#S5.3">5.3</linkhtml>).
            
    
       </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Other antimalarials (e.g., halofantrine, mefloquine).</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>ECG abnormalities including QT prolongation. Avoid concomitant use (
             
     
        <linkhtml href="#S5.3">5.3</linkhtml>, 
             
     
        <linkhtml href="#S7.2">7.2</linkhtml>).
            
    
       </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP3A4 inducers or inhibitors</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Alteration in plasma quinine concentration. Monitor for lack of efficacy or increased adverse events of quinine (
             
     
        <linkhtml href="#S7.1">7.1</linkhtml>).
            
    
       </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>CYP3A4 and CYP2D6 substrates</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Quinine is an inhibitor of CYP3A4 and CYP2D6. Monitor for lack of efficacy or increased adverse events of the co-administered drug (
             
     
        <linkhtml href="#S7.2">7.2</linkhtml>).
            
    
       </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Digoxin</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Increased digoxin plasma concentration (
             
     
        <linkhtml href="#S5.8">5.8</linkhtml>, 
             
     
        <linkhtml href="#S7.1">7.1</linkhtml>).
            
    
       </paragraph>
</td>
</tr>
</tbody>
</table>